Literature DB >> 11275935

Dilation of the aortic root in children infected with human immunodeficiency virus type 1: The Prospective P2C2 HIV Multicenter Study.

W W Lai1, S D Colan, K A Easley, S E Lipshultz, T J Starc, J T Bricker, S Kaplan.   

Abstract

BACKGROUND: Vascular lesions have become more evident in human immunodeficiency virus type 1 (HIV)-infected patients as the result of earlier diagnosis, improved treatment, and longer survival. Aortic root dilation in HIV-infected children has not previously been described. This study was undertaken to determine the prevalence of aortic root dilation in HIV-infected children and to evaluate some of the potential pathogenic mechanisms.
METHODS: Aortic root measurements were incorporated into the routine echocardiographic surveillance of 280 children of HIV-infected women: an older cohort of 86 HIV-infected children and a neonatal cohort of 50 HIV-infected and 144 HIV-uninfected children.
RESULTS: By repeated-measures analyses, mean aortic root measurements were significantly increased in HIV-infected children versus HIV-uninfected children (P values of < or =.04 and < or =.005 at 2 and 5 years of age, respectively, for aortic annulus diameter, sinuses of Valsalva, and sinotubular junction). Heart rate, systolic blood pressure, stroke volume, hemoglobin, and hematocrit were not significantly associated with aortic root size. Left ventricular dilation, increased serum HIV RNA levels, and lower CD4 cell count measurements were associated with aortic root dilation at baseline.
CONCLUSIONS: Mild and nonprogressive aortic root dilation was seen in children with vertically transmitted HIV infection from 2 to 9 years of age. Aortic root size was not significantly associated with markers for stress-modulated growth; however, aortic root dilation was associated with left ventricular dilation, increased viral load, and lower CD4 cell count in HIV-infected children. As prolonged survival of HIV-infected patients becomes more prevalent, some patients may require long-term follow-up of aortic root size.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11275935      PMCID: PMC4357171          DOI: 10.1067/mhj.2001.113757

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  21 in total

Review 1.  The potential role of cytokine-mediated vascular endothelial activation in the pathogenesis of Kawasaki disease.

Authors:  D Y Leung
Journal:  Acta Paediatr Jpn       Date:  1991-12

2.  Large artery vasculopathy in HIV-positive patients: another vasculitic enigma.

Authors:  R Chetty; S Batitang; R Nair
Journal:  Hum Pathol       Date:  2000-03       Impact factor: 3.466

3.  Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group.

Authors:  S E Lipshultz; K A Easley; E J Orav; S Kaplan; T J Starc; J T Bricker; W W Lai; D S Moodie; K McIntosh; M D Schluchter; S D Colan
Journal:  Circulation       Date:  1998-04-07       Impact factor: 29.690

4.  The pediatric pulmonary and cardiovascular complications of vertically transmitted human immunodeficiency virus (P2C2 HIV) infection study: design and methods. The P2C2 HIV Study Group.

Authors: 
Journal:  J Clin Epidemiol       Date:  1996-11       Impact factor: 6.437

5.  Human immunodeficiency virus-associated vasculopathy in transgenic mice.

Authors:  B T Tinkle; L Ngo; P A Luciw; T Maciag; G Jay
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

6.  Clinical profile of HIV-related aneurysms.

Authors:  R Nair; J V Robbs; N G Naidoo; J Woolgar
Journal:  Eur J Vasc Endovasc Surg       Date:  2000-09       Impact factor: 7.069

7.  Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis.

Authors:  M T Grattan; C E Moreno-Cabral; V A Starnes; P E Oyer; E B Stinson; N E Shumway
Journal:  JAMA       Date:  1989 Jun 23-30       Impact factor: 56.272

8.  Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.

Authors:  L M Mofenson; J Bethel; J Moye; P Flyer; R Nugent
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-10

9.  Arteriopathy in children with acquired immune deficiency syndrome.

Authors:  V V Joshi; B Pawel; E Connor; L Sharer; J M Oleske; S Morrison; J Marin-Garcia
Journal:  Pediatr Pathol       Date:  1987

10.  Pattern of arterial aneurysms in acquired immunodeficiency disease.

Authors:  C Marks; S Kuskov
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

View more
  3 in total

1.  Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study.

Authors:  Steven E Lipshultz; Paige L Williams; James D Wilkinson; Erin C Leister; Russell B Van Dyke; William T Shearer; Kenneth C Rich; Rohan Hazra; Jonathan R Kaltman; Denise L Jacobson; Laurie B Dooley; Gwendolyn B Scott; Nicole Rabideau; Steven D Colan
Journal:  JAMA Pediatr       Date:  2013-06       Impact factor: 16.193

2.  Cardiac Effects of Highly Active Antiretroviral Therapy in Perinatally HIV-Infected Children: The CHAART-2 Study.

Authors:  Steven E Lipshultz; James D Wilkinson; Bruce Thompson; Irene Cheng; David A Briston; William T Shearer; E John Orav; Joslyn A Westphal; Tracie L Miller; Steven D Colan
Journal:  J Am Coll Cardiol       Date:  2017-10-31       Impact factor: 24.094

3.  Prevalence and associated risk factors of peripheral artery disease in virologically suppressed HIV-infected individuals on antiretroviral therapy in Kwara state, Nigeria: a cross sectional study.

Authors:  Chidozie Elochukwu Agu; Ikenna Kingsley Uchendu; Augusta Chinyere Nsonwu; Chukwugozie Nwachukwu Okwuosa; Peter Uwadiegwu Achukwu
Journal:  BMC Public Health       Date:  2019-08-20       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.